Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | TP53 | P04637 | 5/20 | 0.78 |
| ▸ | ATM | Q13315 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 7/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243047 | 0.86 | ATM (1.00) | KDM4ETP53ATMMAPTLMNA | |
| SCHEMBL1243710 | 0.83 | MAPT (0.69) | KDM4ETP53ATMMAPTLMNA | |
| SCHEMBL17261472 | 0.83 | MAPT (0.80) | KDM4ETP53ATMMAPTLMNA | |
| SCHEMBL17273797 | 0.83 | ATM (0.71) | KDM4ETP53ATMMAPTLMNA | |
| SCHEMBL1243075 | 0.83 | ATM (0.74) | KDM4ETP53ATMMAPTLMNA | |
| SCHEMBL17261500 | 0.82 | HSD17B10 (0.70) | KDM4ETP53ATMMAPTLMNA | |
| SCHEMBL17273863 | 0.80 | HSD17B10 (0.67) | KDM4ETP53ATMMAPTLMNA | |
| SCHEMBL17261569 | 0.80 | MAPT (0.70) | KDM4ETP53ATMMAPTLMNA | |
| SCHEMBL17273757 | 0.80 | HSD17B10 (0.67) | KDM4ETP53ATMMAPTLMNA | |
| SCHEMBL1243672 | 0.79 | LMNA (1.00) | TP53ATMMAPTLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7888289-B2 | 2,6-Difluoro-N-[2-(2-methyl-4-thiazolyl)ethyl]benzamide; applying an effective and nonphytotoxic amount of the fungicide composition to the plant seeds,leaves and/or fruits of the plants or to the soil; crops; Alternaria | BAYER CROPSCIENCE AG (DE) | 2011-02-15 | — | — | US | claimed |
| US-20090156651-A1 | Heterocyclylethylbenzamide Derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-06-18 | — | — | US | claimed |
| EP-1871744-B1 | NEW HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2009-01-07 | — | — | EP | claimed |
| EP-1871744-A1 | NEW HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2008-01-02 | — | — | EP | claimed |
| WO-2006108792-A1 | NEW HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2006-10-19 | — | — | WO | claimed |
| US-7888289-B2 | 2,6-Difluoro-N-[2-(2-methyl-4-thiazolyl)ethyl]benzamide; applying an effective and nonphytotoxic amount of the fungicide composition to the plant seeds,leaves and/or fruits of the plants or to the soil; crops; Alternaria | BAYER CROPSCIENCE AG (DE) | 2011-02-15 | — | — | US | disclosed |
| US-20090156651-A1 | Heterocyclylethylbenzamide Derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| EP-1871744-B1 | NEW HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2009-01-07 | — | — | EP | disclosed |
| EP-1871744-A1 | NEW HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006108792-A1 | NEW HETEROCYCLYLETHYLBENZAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156651-A1 | Heterocyclylethylbenzamide Derivatives | CYP1A2, CYP51A1, CYP1B1 | KDM4E 1506/4885TP53 3468/4885ATM 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.